Your browser doesn't support javascript.
loading
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu, Weijie; Han, Weiqing; Luo, Hong; Zhou, Fangjian; He, Dalin; Ma, Lulin; Guo, Hongqian; Liang, Chaozhao; Chong, Tie; Jiang, Jun; Chen, Zhiwen; Wang, Yong; Zou, Qing; Tian, Ye; Xiao, Jun; Huang, Jian; Zhu, Shaoxing; Dong, Qiang; Zhang, Xiaoping; Li, Hanzhong; Yang, Xinfeng; Chen, Chunxia; Li, Junliang; Jin, Chunlei; Zhang, Xiaojing; Ye, Dingwei.
Afiliação
  • Gu W; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China.
  • Han W; Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Center, Changsha, China.
  • Luo H; Department of Urology, Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing, China.
  • Zhou F; Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • He D; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Ma L; Department of Urology, Peking University Third Hospital, Beijing, China.
  • Guo H; Department of Urology, Nanjing Drum Tower Hospital, Nanjing, China.
  • Liang C; Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Chong T; Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Jiang J; Department of Urology, Daping Hospital of Army Medical University, Chongqing, China.
  • Chen Z; Department of Urology, The Southwest Hospital of Army Medical University, Chongqing, China.
  • Wang Y; Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Zou Q; Department of Urology, Jiangsu Cancer Hospital, Nanjing, China.
  • Tian Y; Department of Urology, Beijing Friendly Hospital of Capital Medical University, Beijing, China.
  • Xiao J; Department of Urology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China.
  • Huang J; Department of Urology, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou, China.
  • Zhu S; Department of Urology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Dong Q; Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhang X; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Li H; Department of Urology, Peking Union Medical College Hospital, Beijing, China.
  • Yang X; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Chen C; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Li J; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Jin C; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Zhang X; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China. Electronic address: dwyeli@163.com.
Lancet Oncol ; 23(10): 1249-1260, 2022 10.
Article em En | MEDLINE | ID: mdl-36075260
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Protocolos de Quimioterapia Combinada Antineoplásica / Antagonistas de Androgênios Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Protocolos de Quimioterapia Combinada Antineoplásica / Antagonistas de Androgênios Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido